Palvella Therapeutics, Inc.
PVLA · Nasdaq · USD · Market cap $2.1B · 29 employees
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price142.85 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.22)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $207.00 to $267.00, base estimate $232.00 (screen dated 2026-11-20).
- Trend Markup
- Insiders insiders sold, $537,307, latest filing 2026-10-21
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.22, read 2026-11-15
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Palvella Therapeutics, Inc. holds its Markup at $142.85. Elevated stress, defensive posture warranted, held for 64 days.
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 64 days |
| Price at the screen | $142.85 |
| Valuation | N/A trailing · -18.57 forward price to earnings |
| Values screen | FAIL · score 70.0 |
Five Screens: PVLA's Results
FAIL. Accounts receivable
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 1.06% | Below 33% | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 97.35% | Below 49% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Palvella Therapeutics,'s business is fine, but its receivables are about 97% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when PVLA's ethical verdict changes
Today PVLA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 38% discount to our $232.00 fair value.
USD, 2026-11-20 screen. A 38.4% under base.
Street: 16 covering, consensus Strong Buy. Average target +62%.
Rare skin drugs face long clinical odds
A clinical-stage US biotech chasing topical treatments for rare genetic skin diseases sits at a price well below its stated fair value. Yet the opportunity rating lands at none because the ethical screen flags insufficient data on basic financial ratios. That alone stops any deeper look.
The business shows zero profit margins, a sharply negative return on equity and a forward price-to-earnings ratio deep in the red. With no commercial products and an unknown competitive moat, the numbers point to years of cash burn before any revenue arrives.
Risks centre on trial setbacks, repeated equity raises and the complete lack of ethical data to assess governance or supply-chain issues. Fifteen analysts list a higher median target but offer no consensus rating to rely on. Analysis, not advice.
| Forward P/E | -18.6x |
| EPS, trailing | -5.53 |
| EPS, forward | -7.77 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -63.4%not currently earning a positive return on equity |
| FCF yield | -1.33% |
| Debt to equity | 0.13minimal debt: a conservative balance sheet |
| Current ratio | 16.01comfortably covers its short-term bills |
| Short interest, float | 0.20% |
| 52-week range | 72.23 - 179.95 |
| Market cap | $2.1B |
| Employees | 29 |
PVLA-specific watchpoints · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review.
The framework has shifted from markdown to accumulation since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ... Yahoo Finance · 16d ago
- Palvella Therapeutics, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 16d ago
- What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call Yahoo Finance · 16d ago
- Palvella (PVLA) Q3 2026 Earnings Call Transcript Yahoo Finance · 16d ago
- Palvella Therapeutics: Q3 Earnings Snapshot Yahoo Finance · 16d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Goin Kathleen | COO | S - Sale+OE | 4,313 | $537,307 |
| 2026-10-12 | Jenkins George M | Dir | S - Sale | 27,500 | $3,579,476 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $122.09 | -16.3% | · | $837 | -16.3% |
| 2 months | $127.12 | -19.6% | · | $804 | -19.6% |
| 3 months | $136.60 | -25.2% | · | $748 | -25.2% |
| 6 months | $96.78 | +5.6% | · | $1,056 | +5.6% |
| 1 year | $26.23 | +289.5% | · | $3,895 | +289.5% |
| 2 years | $10.01 | +920.7% | · | $10,207 | +920.7% |
| 3 years | $72.80 | +40.3% | · | $1,403 | +40.3% |
| 5 years | $278.40 | -63.3% | · | $367 | -63.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PVLA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.